Iloperidone

Drug Profile

Iloperidone

Alternative Names: Fanapt; Fanaptum; Fiapta; HP 873; ILO 522; Zomaril

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer MegaPharm Ltd; Novartis; PROBIOMED; University of Colorado at Denver; Vanda Pharmaceuticals
  • Class Antipsychotics; Isoxazoles; Piperidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Phase II Post-traumatic stress disorders

Most Recent Events

  • 15 Feb 2017 Vanda Pharmaceuticals expects EMA's decision on Marketing Authorization Application for iloperidone, in second half of 2017
  • 07 Dec 2016 Vanda grants Apotex a license to sell generic Fanapt® in the USA beginning November 2027
  • 30 Aug 2016 The United States Patent and Trademark Office Patent Trials and Appeal Board dismisses Roxane Laboratories request to institute an inter partes review of US Patent No. 9 138 432
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top